Jump to content

glufosfamide small cell lung cancer failed


Recommended Posts

Oct 11 (Reuters) - Threshold Pharmaceuticals Inc (THLD.O: Quote, Profile, Research) said a mid-stage study of its experimental drug glufosfamide to treat small cell lung cancer did not meet the main goal of objective response rate and that it will stop further enrollment in the trial.

The clinical trial used a two-stage design to ensure an adequate response rate to justify complete enrollment and only one confirmed partial response was observed among the 21 patients enrolled in the first stage.

The low response rate indicates that glufosfamide is not sufficiently effective as a single agent for patients with small cell lung cancer, the company said in a statement.

However, patients currently enrolled in the clinical trial will be given the option to continue in the trial, the company added.

Threshold's shares fell more than 18 percent in late electronic trade, after closing at 87 cents Thursday on the Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore)

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.